Indices of Obesity and Cardiometabolic Risk
2011; Lippincott Williams & Wilkins; Volume: 58; Issue: 6 Linguagem: Inglês
10.1161/hypertensionaha.111.180406
ISSN1524-4563
AutoresAdam Whaley‐Connell, James R. Sowers,
Tópico(s)Diet and metabolism studies
ResumoHomeHypertensionVol. 58, No. 6Indices of Obesity and Cardiometabolic Risk Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBIndices of Obesity and Cardiometabolic Risk Adam Whaley-Connell and James R. Sowers Adam Whaley-ConnellAdam Whaley-Connell From the University of Missouri Cardiovascular and Diabetes Center (A.W.-C., J.R.S.), Department of Internal Medicine (A.W.-C., J.R.S.), Department of Medical Pharmacology and Physiology (J.R.S.), and Harry S. Truman Veterans Affairs Medical Center (A.W.-C., J.R.S.), University of Missouri, Columbia, MO. and James R. SowersJames R. Sowers From the University of Missouri Cardiovascular and Diabetes Center (A.W.-C., J.R.S.), Department of Internal Medicine (A.W.-C., J.R.S.), Department of Medical Pharmacology and Physiology (J.R.S.), and Harry S. Truman Veterans Affairs Medical Center (A.W.-C., J.R.S.), University of Missouri, Columbia, MO. Originally published24 Oct 2011https://doi.org/10.1161/HYPERTENSIONAHA.111.180406Hypertension. 2011;58:991–993Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2011: Previous Version 1 See related article, pp 1029–1035The prevalence of obesity in the United States has increased dramatically during the past 25 years.1 Many of the population-based cohort studies in the past decade have defined cardiovascular disease (CVD) risk associated with obesity in the context of diabetes mellitus and hypertension based on measurement of body mass index (BMI).2–4 It is not as clear which clinical measures of obesity to use in risk prediction for diabetes mellitus, hypertension, and CVD morbidity and mortality.2–5 In this issue, Bombelli et al6 explore the predictive value of BMI and waist circumference (WC) on risk prediction for new-onset impaired fasting glucose and diabetes mellitus, hypertension, and left ventricular hypertrophy (LVH). A prospective cohort of ≈3200 individuals from Italy were followed over 10 years with anthropometric measures of weight (BMI and WC), insulin sensitivity (fasting glucose and insulin), blood pressure (in- and out-of-office and ambulatory), and LVH by echocardiography. The population was risk stratified based on BMI and WC to determine new-onset insulin resistance, diabetes mellitus, hypertension, and LVH based on quintiles of relative risk. There was a graded relationship between increasing BMI, in the range of 21 to 29 kg/m2, and increasing risk for new-onset impaired fasting glucose, diabetes mellitus, and hypertension that became significant in the higher (eg, fourth and fifth) quartiles of BMI (>26 kg/m2). Unique to this investigation is the addition of WC for risk prediction, and, concordant with the BMI data, there was a similar graded relationship between increasing WC and risk. Although new-onset ambulatory hypertension and LVH were better predicted by baseline WC than BMI, the overall strength of risk prediction did not increase when adding WC to BMI in adjusted analysis and was comparatively similar on the adjusted risk of developing conditions (receiver-operating characteristic) analysis. These data confirm reports that WC may add limited predictive ability to that of BMI7,8 in cardiometabolic risk prediction.The use of WC in risk prediction has been suggested by recent preclinical and limited clinical data, which support the notion that the association between diabetes mellitus and hypertension with central obesity (eg, WC) is stronger than the association with BMI. Numerous studies using imaging modalities or anthropometric measures (including waist:hip ratio) have provided additional credence that visceral adipose tissue is the major contributor to cardiometabolic complications, such as diabetes mellitus and hypertension.7,8 In this context, obesity is a state of metabolic dysregulation driven by inappropriate activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system despite a state of relative volume expansion.9 RAAS activation in obesity promotes alterations in biochemical mechanisms that include insulin-dependent metabolic signaling. In traditional insulin-sensitive tissues (eg, skeletal muscle, fat, and liver), and in cardiovascular tissue, alterations in insulin metabolic signaling promote impairments in glucose disposal and cardiovascular metabolic signaling that contribute to the development of hypertension and diabetes mellitus (Figure).9 However, increased WC does not always reflect visceral obesity, because it may be related to increased abdominal subcutaneous fat. Although the Figure implies that visceral obesity causes hypertension and diabetes mellitus via insulin resistance, mediated effects on endothelial dysfunction, RAAS activation, and impaired glucose uptake, there are likely other important mechanisms involved.Download figureDownload PowerPointFigure. The relationship between increased visceral adipose tissue with an increased risk for endothelial dysfunction that manifests as hypertension, insulin resistance, and overt diabetes mellitus with left ventricular hypertrophy and long-term cardiovascular risk. RAAS indicates renin-angiotensin-aldosterone system; SNS, sympathetic nervous system; BP, blood pressure.When insulin binds to the insulin resistance, phosphorylation of intracellular substrates, including insulin resistance substrate family members, serves to engage downstream phosphoinositide 3-kinase. Phosphoinositide 3-kinase then binds to the pleckstrin-homology domain in 3-phosphoinositide dependent protein kinase 1, resulting in its phosphorylation and activation of other serine-threonine kinases, including protein kinase B (Akt) and atypical protein kinase C isoforms, which mediate a number of metabolic actions, including GLUT-4 translocation to membranes, endothelial NO synthase activation, and cardiac and vascular relaxation.9,10 In obesity, RAAS and sympathetic nervous system activation promote a pro-oxidative/proinflammatory milieu that contributes to impairments in insulin metabolic signaling resulting in reduced glucose disposal, as well as alterations in cardiovascular function.Much of the clinical work to date, establishing the link between obesity and hypertension, has used in-office readings. Recent work in clinical hypertension has attempted to validate out-of-office and ambulatory monitoring in risk-prediction models.3–6 The longitudinal data from the current study indicate that out-of-office and ambulatory monitoring are equally important to in-office measures in risk stratification of the obese population. Similar to in-office measures, receiver-operating characteristic analysis showed a similar graded relationship over 10 years between BMI and WC and development of new-onset hypertension as determined by out-of-office and ambulatory monitoring measurements.One important long-term risk associated with obesity, hypertension, and impaired insulin metabolic signaling is the development of LVH.10 In preclinical and clinical models, LVH has been validated as a prognosticator for future CVD events. Impaired insulin metabolic signaling, in conjunction with RAAS and sympathetic nervous system activation, is an important factor in the genesis of maladaptive myocardial remodeling.10 In the myocardium, insulin normally promotes glucose uptake and use, mitochondrial ATP production, and endothelial NO synthase activation and inhibits ischemia-induced apoptosis. In conditions of obesity and inappropriate RAAS activation, there is both myocardial hypertrophy and increased fibrosis, leading to LVH and myocardial systolic and diastolic dysfunction.10 Thus, impaired insulin metabolic signaling in cardiovascular tissue may explain the link among obesity, hypertension, LVH, and increased CVD risk (Figure).In summary, BMI is conventionally used as a measure of obesity, yet there has been concern that this measure may not capture the relationship among visceral adiposity, insulin resistance, vascular endothelial dysfunction, and maladaptive cardiac remodeling. The current study6 indicates that baseline BMI and WC had comparable predictive value for new-onset diabetes mellitus and in-office hypertension, whereas new-onset ambulatory hypertension and LVH are better predicted by baseline WC than BMI. Collectively, these longitudinal data from the Pressioni Arteriose Monitorate e Loro Associazioni Study population suggest that the combined use of WC and BMI as obesity indices has potentially greater use than just BMI as a predictor of cardiometabolic risk. Because all of the patients in the Pressioni Arteriose Monitorate e Loro Associazioni Study cohort were white, studies in more racially diverse populations will be necessary to demonstrate the generalizability of the utility of using both BMI and WC as predictive indicators of CVD risk.AcknowledgmentWe thank Brenda Hunter for her assistance in editing the article.Sources of FundingThis research was supported by the National Institutes of Health grants R01 HL73101-01A and R01 HL107910-01 to J.R.S. and R-03 AG040638 and American Society of Nephrology-Association of Specialty Professors-National Institute on Aging Development Grant to A.W.-C., as well as the Veterans Affairs Merit System (0018) to J.R.S. and CDA-2 to A.W.-C.DisclosuresNone.FootnotesThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Correspondence to James R. Sowers, University of Missouri, D109 Diabetes Center HSC, One Hospital Dr, Columbia, MO 65212. E-mail [email protected]missouri.eduReferences1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002; 288:1723–1727.CrossrefMedlineGoogle Scholar2. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, Engelgau MM, Vinicor F. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the US. Diabetes Care. 2004; 27:2806–2812.CrossrefMedlineGoogle Scholar3. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005; 293:1868–1874.CrossrefMedlineGoogle Scholar4. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162:1867–1872.CrossrefMedlineGoogle Scholar5. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083–1096.CrossrefMedlineGoogle Scholar6. Bombelli M, Facchetti R, Sega R, Carugo S, Fodri D, Brambilla G, Giannattasio C, Grassi G, Mancia G. Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage. Hypertension. 2011; 58:1029–1035.LinkGoogle Scholar7. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008; 359:2105–2120.CrossrefMedlineGoogle Scholar8. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004; 79:379–384.CrossrefMedlineGoogle Scholar9. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009; 150:776–783.CrossrefMedlineGoogle Scholar10. Pulakat L, Demarco VG, Ardhanari S, Chockalingam A, Gul R, Whaley-Connell AT, Sowers JR. Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol. Epub ahead of print August 3, 2011.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Xie Z, Zhang M, Song Q, Cheng L, Zhang X, Song G, Sun X, Gu M, Zhou C, Zhang Y, Zhu K, Yin J, Chen X, Li J and Nan F (2022) Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia, Acta Pharmaceutica Sinica B, 10.1016/j.apsb.2022.06.011, Online publication date: 1-Jun-2022. Adegoke O, Ozoh O, Odeniyi I, Bello B, Akinkugbe A, Ojo O, Agabi O and Okubadejo N (2021) Prevalence of obesity and an interrogation of the correlation between anthropometric indices and blood pressures in urban Lagos, Nigeria, Scientific Reports, 10.1038/s41598-021-83055-w, 11:1, Online publication date: 1-Dec-2021. Tian J, Liu Y, Liu Y, Chen K and Lyu S (2017) Cellular and Molecular Mechanisms of Diabetic Atherosclerosis: Herbal Medicines as a Potential Therapeutic Approach, Oxidative Medicine and Cellular Longevity, 10.1155/2017/9080869, 2017, (1-16), . Thota R, Acharya S, Abbott K and Garg M (2016) Curcumin and long-chain Omega-3 polyunsaturated fatty acids for Prevention of type 2 Diabetes (COP-D): study protocol for a randomised controlled trial, Trials, 10.1186/s13063-016-1702-9, 17:1, Online publication date: 1-Dec-2016. Wooten J, Nick T, Seija A, Poole K and Stout K (2016) High-Fructose Intake Impairs the Hepatic Hypolipidemic Effects of a High-Fat Fish-Oil Diet in C57BL/6 Mice, Journal of Clinical and Experimental Hepatology, 10.1016/j.jceh.2016.09.001, 6:4, (265-274), Online publication date: 1-Dec-2016. Crowell J, Davis C, Joung K, Usher N, McCormick S, Dearing E and Mantzoros C (2016) Metabolic pathways link childhood adversity to elevated blood pressure in midlife adults, Obesity Research & Clinical Practice, 10.1016/j.orcp.2015.10.009, 10:5, (580-588), Online publication date: 1-Sep-2016. Guedes E, França G, Lino C, Koyama F, Moreira L, Alexandre J, Barreto-Chaves M, Galante P and Diniz G (2015) MicroRNA Expression Signature Is Altered in the Cardiac Remodeling Induced by High Fat Diets, Journal of Cellular Physiology, 10.1002/jcp.25280, 231:8, (1771-1783), Online publication date: 1-Aug-2016. Barsukov A, Glukhovskoy D, Zobnina M, Mirokhina M, Dydyshko V, Vasiliev V, Kitzishin V and Tishko V (2015) Left ventricular hypertrophy as a marker of adverse cardiovascular risk in persons of different age groups, Advances in Gerontology, 10.1134/S2079057015020022, 5:2, (99-106), Online publication date: 1-Apr-2015. Okeahialam B, Diala U, Uwakwe J, Ejeh I and Ozoilo U (2015) Utility of the Abdominometer: A Novel Contribution to Cardiovascular Anthropometry, Food and Nutrition Sciences, 10.4236/fns.2015.613126, 06:13, (1202-1207), . Jia G and Sowers J (2015) Autophagy: A housekeeper in cardiorenal metabolic health and disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 10.1016/j.bbadis.2014.06.025, 1852:2, (219-224), Online publication date: 1-Feb-2015. Burguera B and Tur J (2015) 3 Medical Management of Obesity Minimally Invasive Bariatric Surgery, 10.1007/978-1-4939-1637-5_3, (15-38), . Jia G, Aroor A and Sowers J (2014) Estrogen and Mitochondria Function in Cardiorenal Metabolic Syndrome The Mitochondrion in Aging and Disease, 10.1016/B978-0-12-394625-6.00009-X, (229-249), . Jia G, Aroor A, Martinez-Lemus L and Sowers J (2014) Overnutrition, mTOR signaling, and cardiovascular diseases, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00262.2014, 307:10, (R1198-R1206), Online publication date: 15-Nov-2014. Chedraui P, Escobar G, Pérez-López F, Palla G, Montt-Guevara M, Cecchi E, Genazzani A and Simoncini T (2014) Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome, Maturitas, 10.1016/j.maturitas.2014.01.014, 77:4, (370-374), Online publication date: 1-Apr-2014. Chedraui P, Pérez-López F, Escobar G, Palla G, Montt-Guevara M, Cecchi E, Genazzani A and Simoncini T (2014) Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome, Maturitas, 10.1016/j.maturitas.2014.06.008, 79:1, (86-90), Online publication date: 1-Sep-2014. Sowers J (2013) Diabetes Mellitus and Vascular Disease, Hypertension, 61:5, (943-947), Online publication date: 1-May-2013. Aroor A, McKarns S, DeMarco V, Jia G and Sowers J (2013) Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance, Metabolism, 10.1016/j.metabol.2013.07.001, 62:11, (1543-1552), Online publication date: 1-Nov-2013. Mandavia C, Pulakat L, DeMarco V and Sowers J (2012) Over-nutrition and metabolic cardiomyopathy, Metabolism, 10.1016/j.metabol.2012.02.013, 61:9, (1205-1210), Online publication date: 1-Sep-2012. Agbo H, Zoakah A, Isichei C, Sagay A, Achenbach C and Okeahialam B (2020) Cardiovascular Anthropometry: What Is Best Suited for Large-Scale Population Screening in Sub-Saharan Africa?, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.522123, 7 December 2011Vol 58, Issue 6 Advertisement Article InformationMetrics © 2011 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.111.180406PMID: 22025378 Originally publishedOctober 24, 2011 PDF download Advertisement SubjectsObesity
Referência(s)